Form 4: Syros Pharmaceuticals' Chief Medical Officer Reports Stock Transactions

Chief Medical Officer of Syros Pharmaceuticals, David Roth, reports acquisition and disposal of common stock and restricted stock units.

Summary

• David Roth, Chief Medical Officer of Syros Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 31, 2024, Roth acquired 2,000 shares of common stock and 13,333 shares of common stock upon vesting of restricted stock units.
• On April 1, 2024, 4,732 shares were disposed of to cover tax withholding at a price of $5.12 per share.
• On April 2, 2024, Roth sold 150 shares of common stock at a weighted average price of $4.9803 per share, with prices ranging from $4.97 to $5.02.
• These sales were executed under a pre-arranged trading plan adopted on March 27, 2023.
• Roth still owns 10,451 shares of common stock after the reported transactions.
• Roth also still owns 4,000 restricted stock units from an award granted on February 15, 2022, vesting in annual installments, and 26,667 restricted stock units from an award granted on February 16, 2023, vesting in annual installments.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by an insider. It doesn't inherently indicate positive or negative sentiment about the company's prospects, but rather reflects personal financial decisions within the bounds of compliance.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with securities regulations.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis to gauge management's sentiment and potential future performance.
• Comparing Roth's transactions to those of other executives in similar biotech companies can provide insights into the overall health and prospects of Syros Pharmaceuticals relative to its peers.
• Companies like Agios Pharmaceuticals (acquired by Servier), Blueprint Medicines, and Deciphera Pharmaceuticals serve as benchmarks for assessing insider activity in the targeted therapy space.

Stakeholder Impact

• Shareholders may be interested in insider transactions as an indicator of management's confidence in the company.
• The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Syros Pharmaceuticals, David Roth, Stock Transactions, Beneficial Ownership, Restricted Stock Units, Rule 10b5-1, Insider Trading